Fourth Quarter and Full Year 2025 Conference Call

March 5, 2026

Legal Disclaimer

Forward-Looking Statements

This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “future,” “growth,” “opportunity,” “well-positioned,” "forecast," "intend," "seek," "target," “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” “project,” “may,” “could,” and “should,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements may be included throughout this presentation, and include, but are not limited to, statements relating to Ambiq Micro’s (“Ambiq,” the “Company,” “we,” “us” or similar terms) expectations around its strategic initiatives, growth trajectory and expected first quarter and full year business outlook. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify including those described in the section titled "Risk Factors" in Ambiq's Quarterly Report on 10-Q for the quarter ended September 30, 2025, as well as in other filings we may make with the SEC in the future. Our expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that our expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this presentation speaks only as of the date of this presentation. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Non-GAAP Financial Measures

Ambiq supplements its reporting of financial information determined under generally accepted accounting principles in the United States of America (GAAP), including the use of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP R&D expenses, non-GAAP SG&A expenses and non-GAAP net loss attributable to common stockholders. These non-GAAP financial measures help management make strategic decisions, establish budgets and operational goals for managing the business, analyzing financial results, and evaluating business performance. Ambiq defines non-GAAP gross profit as gross profit adjusted to exclude expenses not directly attributable to gross profit, such as depreciation and amortization, stock-based compensation and gain on nonmonetary transaction. Ambiq defines non-GAAP gross margin as non-GAAP gross profit as a percentage of net sales. Ambiq defines non-GAAP operating expenses, non-GAAP R&D expenses and non-GAAP SG&A expenses as operating expenses, R&D expenses and SG&A expenses, as applicable, adjusted to exclude expenses not directly attributable to operating expenses, R&D expenses and SG&A expenses, as applicable, such as depreciation and amortization, stock-based compensation, severance costs, IPO-related bonus and IPO and other transaction costs, as applicable. Ambiq defines non-GAAP net loss attributable to common stockholders as net loss attributable to common stockholders adjusted to exclude expenses not directly attributable to the performance of operations, such as income taxes, depreciation and amortization, stock-based compensation, gain on nonmonetary transaction, severance costs, IPO-related bonus, IPO and other transaction costs and warrant valuation.

Ambiq believes these non-GAAP financial measures provide additional tools for investors to use in comparing core business and results of operations over multiple periods with other companies in the industry, many of which present similar non-GAAP financial measures. However, Ambiq's presentation of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP R&D expenses, non-GAAP SG&A expenses, non-GAAP net loss attributable to common stockholders may not be comparable to similarly titled measures reported by other companies due to differences in the way that these measures are calculated. These non-GAAP measures have limitations, and should not be considered as the sole measures of our performance and should not be considered in isolation from, or as a substitute for, the most comparable measure calculated in accordance with GAAP.

Today's Agenda

Charlene Wan
Vice President of Corporate Marketing & Investor Relations

Welcome

Fumihide Esaka
Chief Executive Officer

Business Update

Jeffrey Winzeler
Chief Financial Officer

Results and Outlook

Business Update

ambiq

Executive Summary

Strong 2025 net sales growth on accelerated edge AI adoption

Platform leadership driving expanded customer usage

Increasing design funnel diversity across end markets

Advancing product roadmap to power edge AI innovation

Strong business momentum and positioned for future growth

Fourth Quarter Highlights

Net sales exceeded guidance

- Stronger-than-expected end user demand
- Expedited orders accelerated late-quarter demand

Sequential net sales growth

- Continued demand for customers' products
- Customers extending product use across more devices
- Upgrades to Apollo5, supporting more advanced capabilities

$20.7M
Net Sales

45.5%
Non-GAAP Gross Margin[1]

$9.4M
Non-GAAP Gross Profit[1]

1. Non-GAAP gross margin and non-GAAP gross profit are non-GAAP financial measures. Please refer to the Appendix for reconciliation to the nearest GAAP measure.

2025 Highlights

Grew net sales and non-GAAP gross profit[1] sequentially in every quarter of the year

Non-GAAP gross profit[1] +36.3% year-over-year and delivered highest ever annual gross profit

Secured new customers across end markets

Including large wearables customer

Increased diversity of design funnel

Across medical, industrial and smart building markets

Launched new hardware and software products

Enabling more advanced edge AI

Successfully completed upsized initial public offering in 3Q25 and follow-on offering in 1Q26

Raised net proceeds of $102.7M and $76.8M from IPO and follow-on, respectively

1. Non-GAAP gross profit is a non-GAAP financial measure. Please refer to the Appendix for reconciliation to the nearest GAAP measure.

Secular Tailwinds Powering Our Growth

Customers increasingly incorporating sophisticated edge AI capabilities to drive differentiation and end-customer demand

Smart Rings

Smart Watches

Smart Bands

Smart Eyewear

- Customers expected to introduce next-generation models in 2026 with more advanced features
- Additional, scaled global customer expected to move into mass production in 2026
- Anticipate additional volumes from products introduced in late 2025 that will continue to scale in 2026
- Expect customers will continue to migrate to Apollo5 and Apollo330, enabling greater performance and AI capability

ambiq

Strong and Diverse Edge AI Pipeline


Ear Protection


Worker Safety


Smart Grid Sensors


Continuous Glucose Monitors


Moisture Sensors


Hearing Aids

Vibrational Sensors


Cardiac Monitors


Water & Gas Meters

Case Study:
RONDS

- Leading intelligent industrial equipment solutions provider through its Novaseer brand
- Using SPOT to enable large-scale use of always-on, battery-powered AI sensors
- Unlocks new growth opportunities in the industrial edge for Ambiq

Unlocking Access to New Markets and Edge AI Use Cases

more radio protocols → extended temp → lower prices → smaller form factors

APOLLO510 — **APOLLO510 LITE** — **APOLLO330**

- Personal Devices
- Industrial Edge
- Smart Home & Buildings
- Medical & Healthcare

New Software Tools and AI Models

heliaAOT® | heliaRT® | heartKIT | soundKIT

ambiq

Unlocking Access to New Markets and Edge AI Use Cases

more radio protocols | extended temp | lower prices | smaller form factors | *mass market AI* | *derivatives*

APOLLO510 — **APOLLO510 LITE** — **APOLLO330** — **APOLLO340**

Personal Devices

Industrial Edge

Smart Home & Buildings

Medical & Healthcare

New Software Tools and AI Models

heliaAOT® | heliaRT® | heartKIT | soundKIT | compressionKIT

ambiq

Unlocking Access to New Markets and Edge AI Use Cases

more radio protocols | extended temp | lower prices | smaller form factors | *mass market AI* | *derivatives* | *npu* | *vision*

APOLLO510 — **APOLLO510 LITE** — **APOLLO330** — **APOLLO340** — **ATOMIQ**

- Personal Devices
- Industrial Edge
- Smart Home & Buildings
- Medical & Healthcare

New Software Tools and AI Models

heliaAOT® | heliaRT® | heartKIT | soundKIT | compressionKIT | visionKIT

ambiq

Results & Outlook

2025 Quarterly Financial Results

Net Sales

(dollars in millions)



Non-GAAP Gross Profit[1]

(dollars in millions)



Non-GAAP Gross Margin[1]



Ambiq delivered record full-year gross profit with sequential net sales and non-GAAP gross profit increases in every quarter of the year

1. Non-GAAP gross profit and non-GAAP gross margin are non-GAAP financial measures. Please refer to the Appendix for reconciliation to the nearest GAAP measure.

Fourth Quarter Key Takeaways

- Marked the highest net sales quarter of FY25 and exceeded guidance
- Results reflect strategic repositioning, with 8.6% of net sales from mainland China, down from 50.0% in 4Q24
- Non-GAAP gross margin[1] improved 0.7 pts sequentially, reflecting higher sales to customers deploying multiple edge AI capabilities
- Increased non-GAAP operating expense to support Atomiq and Apollo development and strategic sales and marketing initiatives

	4Q25	3Q25
Net Sales	**$20.7M** *+2.0% y/y*	**$18.2M** *-10.4% y/y*
Non-GAAP Gross Profit[1]	**$9.4M** *+75.5% y/y*	**$8.1M** *+16.8% y/y*
Non-GAAP Gross Margin[1]	**45.5%** *+19.1 pts y/y*	**44.8%** *+10.4 pts y/y*
Non-GAAP Op Ex[1]	**$16.6M** *+26.8% y/y*	**$13.2M** *+1.1% y/y*
Non-GAAP Net Loss Per Share Attributable to Common Stockholders[1]	**$(0.32)**	**$(0.32)**

1. Non-GAAP gross profit, non-GAAP gross margin, non-GAAP op ex, non-GAAP R&D, non-GAAP SG&A and non-GAAP net loss per share attributable to common stockholders are non-GAAP financial measures. Please refer to the Appendix for reconciliation to the nearest GAAP measure.

Strong Balance Sheet

Product Innovation

Enhanced Sales and Marketing

As of 12/31/25

Total Assets
$184.7 Million

Total Liabilities
$22.2 Million

No Outstanding Debt

Follow-on proceeds to accelerate Atomiq and Apollo family development to capture a rapidly expanding market opportunity

Financial Outlook[1]

1Q26 Drivers

- Strong underlying demand, ongoing customer launches and Apollo5 adoption
- Ramping of Apollo5, with improved yield as it scales through the year
- Increased investment to support strategic growth priorities
- Weighted average share count of 20.38M shares outstanding

FY26 Expectations

- Strong net sales growth driven by new launches, customer ramps, recent introductions, and Apollo5 adoption
- Non-GAAP gross margin supported by yield gains; potential industry cost and supply chain pressures
- Non-GAAP operating expense up ~$30M YOY on accelerated Atomiq and Apollo development
- Non-GAAP operating expense includes $7M - $10M of IP purchases during the year, with non-linear impact

1Q 2026 Outlook

Net Sales	*$21.0M - $22.0M*
Non-GAAP Gross Margin[2]	*44.0% - 45.0%*
Non-GAAP Op Ex[2]	*$18.0M - $18.5M*
Non-GAAP Net Loss Per Share Attributable to Common Stockholders[2]	*$(0.39) – $(0.33)*

1. As of 3/5/2026
2. Non-GAAP gross margin, non-GAAP op ex and non-GAAP net loss per share attributable to common stockholders are non-GAAP financial measures.

Well Positioned for Future Growth

Demonstrated strong execution with sequential net sales and non-GAAP gross profit growth in 2025

Accelerating demand for edge AI supports top-line momentum

Continuing to expand into key end markets through Apollo and software innovation

Enabling heavier edge AI capabilities and expanding our reach with Atomiq and Apollo launches

Driving margin expansion from improved yields and continued end-market diversification

Maintaining strong liquidity with ample dry powder to invest in strategic growth initiatives

Appendix:
Non-GAAP Reconciliations

Non-GAAP Financial Measures

	Three Months ended December 31,		Year ended December 31,		Three Months ended September 30,
($ in thousands)	2025	2024	2025	2024	2025
Net loss attributable to common stockholders	$ (10,679)	$ (10,191)	$ (36,461)	$ (42,385)	$ (9,002)
Add:					
Income taxes	19	3	40	28	3
Depreciation and amortization	1,648	1,695	7,215	6,246	1,754
Stock-based compensation	3,151	863	6,835	5,174	2,068
Gain on nonmonetary transaction	—	—	(1,600)	(1,600)	—
Severance costs	—	—	—	706	—
IPO-related bonus	—	—	1,200	—	1,200
IPO and other transaction costs	—	97	1,793	551	—
Warrant valuation	—	—	60	(51)	—
Non-GAAP net loss attributable to common stockholders	$ (5,861)	$ (7,533)	$ (20,918)	$ (31,331)	$ (3,977)
Non-GAAP EPS	$ (0.32)	$ (19.52)	$ (2.62)	$ (83.90)	$ (0.32)

Non-GAAP Financial Measures

	Three Months ended December 31,		Year ended December 31,		Three Months ended March 31,	Three Months ended June 30,	Three Months ended September 30,
($ in thousands)	2025	2024	2025	2024		2025	
Gross profit	$ 8,859	$ 5,048	$ 32,095	$ 24,291	$ 8,389	$ 7,170	$ 7,677
Add:							
Depreciation and amortization	475	252	1,906	895	562	430	439
Stock-based compensation	102	76	227	356	60	40	25
Gain on nonmonetary transaction	—		(1,600)	(1,600)	(1,600)	—	—
Non-GAAP gross profit	$ 9,436	$ 5,376	$ 32,628	$ 23,942	$ 7,411	$ 7,640	$ 8,141
Gross Margin	42.7%	24.8%	44.3%	31.9%	53.3%	40.1%	42.3%
Non-GAAP Gross Margin	45.5%	26.4%	45.0%	31.5%	47.1%	42.7%	44.8%

Non-GAAP Financial Measures

	Three Months ended December 31,		Year ended December 31,		Three Months ended September 30,
($ in thousands)	**2025**	**2024**	**2025**	**2024**	**2025**
Operating expenses	$ 20,821	$ 15,419	$ 71,638	$ 64,904	$ 17,720
Less:					
Depreciation and amortization	1,173	1,443	5,309	5,351	1,315
Stock-based compensation	3,049	787	6,608	4,818	2,043
Severance	—	—	—	706	—
IPO-related bonus	—	—	1,200	—	1,200
IPO and other transaction costs	—	97	1,793	551	—
Non-GAAP operating expenses	$ 16,599	$ 13,092	$ 56,728	$ 53,478	$ 13,162

ambiq

Non-GAAP Financial Measures

($ in thousands)	Three Months ended December 31,		Year ended December 31,		Three Months ended September 30,
Research and development	**2025**	**2024**	**2025**	**2024**	**2025**
Operating expenses	$ 12,012	$ 8,773	$ 38,486	$ 37,168	$ 8,889
Less:					
Depreciation and amortization	1,136	1,410	5,061	5,116	1,279
Stock-based compensation	1,609	396	2,589	2,416	263
Severance	—	—	—	439	—
IPO-related bonus	—	—	433	—	433
Non-GAAP operating expenses	$ 9,268	$ 6,967	$ 30,403	$ 29,196	$ 6,915

ambiq

Non-GAAP Financial Measures

($ in thousands)	Three Months ended December 31,		Year ended December 31,		Three Months ended September 30,
Selling, general, and administrative	**2025**	**2024**	**2025**	**2024**	**2025**
Operating expenses	$ 8,809	$ 6,646	$ 33,152	$ 27,736	$ 8,831
Less:					
Depreciation and amortization	37	33	248	235	36
Stock-based compensation	1,440	392	4,019	2,402	1,781
Severance	—	—	—	267	—
IPO-related bonus	—	—	767	—	767
IPO and other transaction costs	—	97	1,793	551	—
Non-GAAP operating expenses	$ 7,331	$ 6,124	$ 26,324	$ 24,282	$ 6,247

Ambiq: Enabling AI Everywhere with SPOT